Full Text
Cost Effectiveness Analysis Of Evolocumab, A PCSK9 Inhibitor, From The US Societal Perspective

Abstract

Authors

BD Innis JW Hay

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×